Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:38 AM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 745–768 of 7,451 matching trials from the live ClinicalTrials.gov search.
Filters: Denver, Colorado Clear all
Completed Phase 2 Interventional Results available

MT-8554 for Reduction of Vasomotor Symptoms in Postmenopausal Women

NCT03291067
View directory record Official record
Conditions
Menopause Hot Flashes
Interventions
MT-8554 1mg, MT-8554 5mg, MT-8554 10mg, Placebo
Drug
Lead sponsor
Tanabe Pharma America, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
63
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 50 more
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Results available

Efficacy, Safety, and Tolerability of Topical Terbinafine in Patients With Mild to Moderate Toenail Fungus of the Big Toenail

NCT00443898
View directory record Official record
Conditions
Onychomycosis
Interventions
terbinafine, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
20
States / cities
Birmingham, Alabama • San Diego, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Nov 3, 2026, 11:38 AM EST
Completed No phase listed Observational Accepts healthy volunteers

A Survey of Complementary and Conventional Medicine Use Patterns in the Veteran Population

NCT01502475
View directory record Official record
Conditions
Alternative Medicine, Attitudes, Beliefs, Veterans
Interventions
Not listed
Lead sponsor
VA Eastern Colorado Health Care System
Federal
Eligibility
18 Years to 89 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
2
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 2 Interventional

Study Testing the Biologic Activity and Safety of a Immunotherapeutic in Patients With Newly Diagnosed Advanced Stage Kidney Cancer in Combination With a Marketed Renal Cell Carcinoma Treatment

NCT00678119
View directory record Official record
Conditions
Renal Cell Carcinoma
Interventions
AGS-003, Sunitinib
Biological · Drug
Lead sponsor
Argos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
12
States / cities
Duarte, California • Los Angeles, California • Denver, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2013 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort II)

NCT04090957
View directory record Official record
Conditions
Vasomotor Symptoms, Menopausal Symptoms
Interventions
Estetrol oral tablet, Placebo oral tablet
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
1,015 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
111
States / cities
Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2025 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 2 Interventional

Study of CTS-1027 in Hepatitis C Patients

NCT00570336
View directory record Official record
Conditions
Chronic Hepatitis C Virus Infection
Interventions
CTS-1027, Placebo
Drug · Other
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • La Jolla, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2010 · Synced Nov 3, 2026, 11:38 AM EST
Recruiting Phase 2 Interventional

A Phase 2 Trial of Dotinurad in Xanthine Oxidase Inhibitor (XOI) Intolerant/Uricase Failure Gout Participants

NCT07535034
View directory record Official record
Conditions
Gout
Interventions
Dotinurad, Placebo
Drug · Other
Lead sponsor
Crystalys Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
41
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional

T-20 With Anti-HIV Combination Therapy for Patients With Prior Anti-HIV Drug Treatment and/or Drug Resistance to Each of the Three Classes of Approved Anti-HIV Drugs

NCT00008528
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
16 Years and older
Enrollment
525 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
34
States / cities
Birmingham, Alabama • Phoenix, Arizona • Beverly Hills, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Results available

Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma

NCT00004228
View directory record Official record
Conditions
Lymphoma
Interventions
asparaginase, cyclophosphamide, cytarabine, daunorubicin hydrochloride, dexamethasone, doxorubicin hydrochloride, leucovorin calcium, mercaptopurine, methotrexate, prednisone, thioguanine, vincristine sulfate, radiation therapy
Drug · Radiation
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 30 Years
Enrollment
393 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2015
U.S. locations
152
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 127 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Nov 3, 2026, 11:38 AM EST
Terminated Not applicable Interventional

Sensor Augmented Pump (SAP) Therapy for Inpatient CFRD Management

NCT03939065
View directory record Official record
Conditions
Cystic Fibrosis-related Diabetes, Cystic Fibrosis Pulmonary Exacerbation, Cystic Fibrosis in Children
Interventions
Sensor Augmented Pump Therapy, Standard of Care with CGM
Device
Lead sponsor
University of Colorado, Denver
Other
Eligibility
8 Years to 25 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Nov 3, 2026, 11:38 AM EST
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Etripamil for the Termination of Spontaneous Paroxysmal Supraventricular Tachycardia (PSVT).

NCT03464019
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia
Interventions
Etripamil, Placebo, Etripamil Test Dose
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
1,097 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Cerritos, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2024 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 2Phase 3 Interventional Results available

Cocaine Use Reduction With Buprenorphine

NCT01402492
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Buprenorphine + Naltrexone, Placebo + Naltrexone
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 65 Years
Enrollment
302 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional

A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD

NCT00215436
View directory record Official record
Conditions
COPD
Interventions
Formoterol Fumarate
Drug
Lead sponsor
Dey
Industry
Eligibility
40 Years and older
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
44
States / cities
Jasper, Alabama • Phoenix, Arizona • Tuscon, Arizona + 40 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2010 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Results available

Management of LDL-cholesterol With Inclisiran + Usual Care Compared to Usual Care Alone in Participants With a Recent Acute Coronary Syndrome

NCT04873934
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Inclisiran
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
88
States / cities
Jonesboro, Arkansas • Bakersfield, California • Fresno, California + 75 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2025 · Synced Nov 3, 2026, 11:38 AM EST
Completed No phase listed Observational

Asthma and Obesity: Observational

NCT03460834
View directory record Official record
Conditions
Asthma, Obesity
Interventions
Not listed
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
21 Years to 64 Years
Enrollment
333 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
2
States / cities
Aurora, Colorado • New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2021 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Results available

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

NCT00006164
View directory record Official record
Conditions
Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions
Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Results available

Aurinia Renal Response in Active Lupus With Voclosporin

NCT03021499
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Voclosporin, Placebo Oral Capsule
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
59
States / cities
Huntsville, Alabama • Phoenix, Arizona • Beverly Hills, California + 47 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Nov 3, 2026, 11:38 AM EST
Recruiting Phase 2Phase 3 Interventional

Study to Evaluate the Pharmacodynamics, Safety and Efficacy of SKY-0515 in Participants With Huntington's Disease

NCT07378644
View directory record Official record
Conditions
Huntington Disease
Interventions
SKY-0515, SKY-0515 Placebo
Drug
Lead sponsor
Skyhawk Therapeutics, Inc.
Industry
Eligibility
25 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Englewood, Colorado • Boston, Massachusetts • Charlestown, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Nov 3, 2026, 11:38 AM EST
Completed No phase listed Observational

A Study to Monitor the Health of Participants in HIVNET 014 Who Become Infected With HIV-1

NCT00001121
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 60 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
11
States / cities
San Francisco, California • Denver, Colorado • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2008 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 3 Interventional Results available

Efficacy and Safety of Semaglutide Versus Dulaglutide as add-on to Metformin in Subjects With Type 2 Diabetes.

NCT02648204
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
semaglutide, Dulaglutide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
1,201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
100
States / cities
Tuscumbia, Alabama • Chandler, Arizona • Phoenix, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2019 · Synced Nov 3, 2026, 11:38 AM EST
Completed Phase 2 Interventional Results available

Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Oral Cancers

NCT03515538
View directory record Official record
Conditions
Oral Mucositis
Interventions
RRx-001, Cisplatin for injection, Radiation Therapy
Drug · Radiation
Lead sponsor
EpicentRx, Inc.
Industry
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
12
States / cities
Santa Monica, California • Denver, Colorado • Washington D.C., District of Columbia + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Nov 3, 2026, 11:38 AM EST
Not listed Phase 2 Interventional Accepts healthy volunteers

Drospirenone-only Pill as Emergency Contraception

NCT05675644
View directory record Official record
Conditions
Contraception
Interventions
Drospirenone-only pill
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 35 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Nov 3, 2026, 11:38 AM EST
Active, not recruiting Phase 3 Interventional

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT04095364
View directory record Official record
Conditions
Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma, Stage II Fallopian Tube Cancer AJCC v8, Stage II Ovarian Cancer AJCC v8, Stage II Primary Peritoneal Cancer AJCC v8, Stage III Fallopian Tube Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage III Primary Peritoneal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Imaging Procedure, Letrozole, Paclitaxel
Procedure · Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
883
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Goodyear, Arizona + 562 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Nov 3, 2026, 11:38 AM EST
Terminated Phase 4 Interventional Results available

Safety and Efficacy of Pimecrolimus Cream 1% in Atopic Disease Modification

NCT00124709
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Corticosteroid
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
3 Months to 18 Months
Enrollment
1,091 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
36
States / cities
Birmingham, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2011 · Synced Nov 3, 2026, 11:38 AM EST